CONNECT WITH US
HealthTech

HealthTech

Bristol Myers defends pipeline, reinforces later-stage BD interest

Endpoints News logo

Published on

Add as a preferred source on Google
Bristol Myers defends pipeline, reinforces later-stage BD interest

Bris­tol My­ers Squibb is reem­pha­siz­ing its plan to stave off one of the in­dus­try’s most daunt­ing patent cliffs.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

R&D chief Dean Li says Mer­ck out­flanked ri­vals with its sac-TMT can­cer pro­gram October 29, 2026

For­ma­tion Bio un­veils $600M fund to li­cense and test more drugs October 28, 2026

One-per­son biotechs and an 'age of mir­a­cles': An­throp­ic re­veals next leg of its bio­phar­ma vi­sion

Up­dat­ed: Lil­ly beats rev­enue fore­casts, lift­ing full-year out­look for third straight quar­ter



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.